Compare ALSN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | ROIV |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United Kingdom |
| Employees | 4000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 25.1B |
| IPO Year | 2011 | 2021 |
| Metric | ALSN | ROIV |
|---|---|---|
| Price | $127.27 | $41.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $117.57 | $28.94 |
| AVG Volume (30 Days) | 645.0K | ★ 7.9M |
| Earning Date | 05-04-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $3,010,000,000.00 | $8,260,000.00 |
| Revenue This Year | $94.98 | N/A |
| Revenue Next Year | $5.30 | $744.61 |
| P/E Ratio | $36.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.01 | $13.83 |
| 52 Week High | $137.62 | $42.50 |
| Indicator | ALSN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 66.10 |
| Support Level | $110.38 | $33.15 |
| Resistance Level | $136.14 | N/A |
| Average True Range (ATR) | 4.07 | 1.37 |
| MACD | -0.36 | 0.53 |
| Stochastic Oscillator | 45.81 | 78.11 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.